Featured Stories

  • The COVID Heart - One Year After SARS-CoV-2 Infection, Patients Have an Array of Increased Cardiovascular Risks

    The COVID Heart - One Year After SARS-CoV-2 Infection, Patients Have an Array of Increased Cardiovascular Risks Published March 2, 2022: JAMA doi: 10.1001/jama.2022.2411

    Learn More

  • Long-term Cardiovascular Outcomes of COVID-19

    Long-term cardiovascular outcomes of COVID-19 Published Feb. 7, 2022: Nature Medecine  https://doi.org/10.1038/s41591-022-01689-3  

    Learn More

  • Understanding Pulmonary Arterial Hypertension Outcome Measures

    Pulmonary arterial hypertension (PAH) is a rare, life-threatening condition characterized by elevated blood pressure in the arteries which carry blood from the heart to the lungs. The high blood...

    Learn More

  • Calgary-based biotech firm specializes in instructing cells to fight complex diseases

    Imagine a world where a host of diseases and conditions caused by non-beneficial instructions from our DNA could be treated simply by instructing our cells to ignore those signals. That science is...

    Learn More

  • Health Matters: Alberta-developed drug could help prevent long COVID

    Health Matters February 2: Calgary company Resverlogix has developed a drug that could not only stop COVID-19 illness from progressing, it also has potential to prevent chronic symptoms, or long...

    Learn More

  • Calgary Company's COVID Drug Going to Phase Two Trials

    Calgary-based biotech company Resverlogix moves into a phase two clinical trial for an oral treatment Apabetalone for COVID-19. And they are looking for patients to participate in the study....

    Learn More

  • Made-in-Alberta drug being tested on COVID-19 patients

    New drug trial to treat COVID-19 patients has been launched at the University of Alberta. Hiba Kamal-Choufi reports.

    Learn More

  • 'Exciting breakthrough': COVID-19 drug trial to take place in Edmonton

    Trials for a Canadian-developed COVID-19 treatment are set to begin at the University of Alberta. CTV News Edmonton - Aired January 24, 2022

    Learn More

  • An Alberta-developed oral treatment for COVID-19 has begun testing at the University of Alberta hospital

    J'lyn Nye interviews RVX President & CEO Donald McCaffrey about our Phase 2b COVID-19 Clinical Trial on 630 CHED

    Learn More

  • Some COVID-19 patients in Edmonton begin potential trial treatment, apabetalone, an Alberta-developed drug

    By Kellen Taniguchi Edmonton Journal, January 18, 2022  

    Learn More

  • Epigenetic Therapies Start Operating Outside the Lines

    Drug developers are sourcing novel structures, bridging transcriptional and signaling domains, and exploring applications beyond oncology GEN: Genetic Engineering and Biotechnology News...

    Learn More

  • Resverlogix in Active Discussions with Morocco

    Resverlogix is in active discussions for COVID-19 clinical studies in Morocco involving apabetalone.

    Learn More

  • Donald McCaffrey at Benzinga All Access

    Resverlogix President & CEO Donald McCaffrey presents at Benzinga All Access conference 2021

    Learn More

  • Resverlogix: The Future of Drug Development

    Clip of Donald McCaffrey, President & CEO of Resverlogix which aired on Fox News December 18, 2021.   © 2021 www.B-TV.com . All Rights Reserved.  

    Learn More

  • Apabetalone meets primary endpoint in PAH pilot study

    Resverlogix reported that its lead drug apabetalone met its primary endpoint in a pulmonary arterial hypertension or ‘PAH’ investigator led pilot study. Watch the news...

    Learn More

  • EVERSANA & Resverlogix Discuss Partnership On PharmaVOICE Webinar

    Rohit Sood, EVP, COMPLETE Commercialization, EVERSANA / Donald McCaffrey, President & CEO, Resverlogix: Next Generation Commercial Innovation: Moving From Promise to Practice. 

    Learn More

  • Donald McCaffrey featured on Innovators with Jane King

    Donald McCaffrey, President & CEO of Resverlogix featured on Innovators with Jane King. Latest updates on the Company's COVID-19 program.

    Learn More

  • COVID-19 Program Update with Donald McCaffrey

    CEO Donald McCaffrey joined PBA à Noon, for a live webinar and Q&A, to discuss the latest developments in Resverlogix' COVID-19 program.

    Learn More

  • Health Canada Authorizes COVID-19 Clinical Study

    Resverlogix receives "No Objection Letter" from Health Canada, approving the COVID-19 Clinical Trial Application for apabetalone.

    Learn More

  • Apabetalone May Prevent Heart Damage Caused by COVID-19

    COVID-19 affects not only lung and respiratory tissue but can injure your heart as well. One study, published in the Journal of the American Medical Association, found that 78% of recently...

    Learn More

  • Balancing Epigenetics in the Treatment of Chronic Kidney Disease

    Kidneys are the body’s filtration system . They clean our blood, removing waste and helping manage blood pressure by controlling the outflow of water. Unfortunately, when these filters...

    Learn More

  • Targeting Epigenetics as a New Therapy in Vascular Disease and Dementia

    Cardiovascular disease literally means disease of the heart and blood vessels, but it can cause additional life-altering complications that we might not initially associate with the disease,...

    Learn More

  • The Faces of Cardiovascular Disease: Series Final

    This is the final article of the mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men...

    Learn More

  • The Faces of Cardiovascular Disease: Part 4

    This article is part of a mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women...

    Learn More

  • The Faces of Cardiovascular Disease: Part 3

    This article is part of a mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women...

    Learn More

  • The Faces of Cardiovascular Disease: Part 2

    This article is part of a mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women...

    Learn More

  • The Faces of Cardiovascular Disease: Part 1

    This article is part of a mini-series we are calling The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of...

    Learn More

  • Apabetalone: A Relative Size Animation

    Our lead compound – apabetalone – is the first small molecule of its kind with potentially important benefits for patients with high-risk cardiovascular and other chronic diseases. But...

    Learn More

  • The Faces of Cardiovascular Disease: Part 3

    This article is part of a mini-series, The Faces of Cardiovascular Disease, looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women around the world. First, be sure to read part 1 and part 2. In this installment, we explore the impact of type 2 diabetes on a fictional person’s life; elements of this story have been inspired by front line doctors whom we have a close connection with. Keep reading for information on future planned articles.

    How much time do you spend thinking about food?

    For me, healthy and active, food comes to mind when I’m hungry. I’m a horrible planner – the choices I make about what to put into my body are made on the fly. I try to eat “healthy”, but that “healthy” spectrum can be quite broad and is definitely influenced by my mood.

    For my dad, after 5 heart attacks, an extremely long list of meds to regulate his blood pressure, cholesterol, and blood glucose levels are part of his daily regime. Tracking what he eats NEEDS to be a priority. Those “healthy choices” I make? Turns out they aren’t so healthy when your body’s glucose handling system is compromised.

    Yogurt? My dad’s favorite brand spikes his glucose levels from a nice regulated 5 mmol/L to a spectacular 15. Half a club sandwich (without the fries he really wanted)? 17.  And that’s with all those diabetes meds he’s on. Just think what a blueberry cobbler could do!

    Every one of us will experience a peak in our blood glucose after eating. My blood glucose will level off in the 4-8 mmol/L range within an hour or two of that meal. For my dad, however, his glucose will peak far higher than mine, and if it exceeds the capacity of his diabetes meds, it will stay elevated. He’ll need an insulin injection to return his blood glucose to the normal range. That high sustained glucose – it will do slow insidious damage to his body without him even knowing it.

    So my dad needs to be vigilant about what he eats and actively avoid foods with a high glycemic index. Being able to stay in that normal blood glucose range develops with experience. That experience – it comes from pricking your finger – a lot! The glucose monitor knows what your eyes cannot tell you. Some foods masquerading as healthy will do you no good.

     

    Diabetes is a slowly developing, cumulative disease. It results from uncontrolled, sustained high blood glucose levels (hyperglycemia). Normally, insulin released from pancreatic beta cells signals muscle, red blood cells, and fat cells to absorb glucose and move it out of the blood. Consistent high glucose renders these cells insensitive to insulin (insulin resistance), so blood glucose levels stay high. This presses the pancreatic beta cells into overdrive, pushing them to produce even more insulin. These exhausted cells turn off, and eventually die, promoting insulin deficiency. In type 2 diabetes, persistent overworking and challenging the glucose handling system leads to insulin resistance and deficiency – and unresolved, sustained high blood glucose.

    High blood glucose irritates blood vessel linings. It causes inflammation and damage to the vasculature. This inflammation is a major driver of atherosclerosis. Heart disease or stroke is twice as likely to be the cause of death for diabetics compared to non-diabetics.

    Vascular damage also undermines the function of the organs they nourish. Diabetic retinopathy develops as the tiny blood vessels that feed the back of the eye are blocked. Vision changes in both eyes are a sign of this problem. For more than 60% of patients with diabetes, diabetic retinopathy is an issue. Proper kidney function also relies on blood flow through tiny blood vessel clusters (glomeruli) to filter waste from blood. Diabetic nephropathy arises as the glomeruli are damaged by high glucose and high blood pressure. Diabetics are 40% more likely to develop kidney disease than non-diabetics.

    Vascular damage caused by high blood glucose often spreads inflammation to nearby nerves. Painful diabetic neuropathies are triggered by the nerve damage wherever it occurs. Often the pain or numbness is felt in the legs and feet, but it may localize to the digestive system, urinary tract, blood vessels and heart. Up to half of diabetics will experience a neuropathy.   

     

    My takeaway – I need to eat foods that aren’t a constant overwhelming challenge to my glucose handling system. After all, my risk for developing diabetes is increased by my family history. I’ll have to be pro-active to keep my pancreatic beta cells in working order for a good long while.

    So how am I going to choose what “healthy” foods to eat? Well, not too long ago some bright minds got together and revised the Canada Food Guide. Seeing as it stresses unprocessed, whole foods – particularly fruits, veggies, and nuts that are easy to grab, it suits my lifestyle. I’ll try it out as a basis for my choices going forward.

    And my dad? His diabetes diagnosis is not a death sentence. In fact he’s been living a good long time with it. But he does need to be constantly aware of what he’s eating. His body can repair itself from the damage done by high blood glucose if he can keep it in check. Oh - and hopefully he throws in some cardio. Getting that heart rate up gets the blood pumping to all those needy organs!

    At Resverlogix, we continue to research the biology underlying CVD and other multi-factorial diseases. Click here for our published findings. We endeavour to explore the human side of the problems associated with these diseases. This allows us to ultimately better inform the novel products we develop and to improve the quality of patients’ lives.

    Stay tuned for the next article in this series where we will explore CVD risk factors unique to kidney disease and the additional biological processes that contribute to both. In addition, we will explore new and innovative treatment options.